Figure 5.

Niclosamide inhibited CRPC tumor growth in vivo. (A) Mice bearing 22Rv1 xenografts were treated with vehicle (1% DMSO and 1% Tween-80 in PBS), 25 mg/kg or 50 mg/kg of niclosamide for 4 weeks. Tumor volumes were measured twice weekly and the observed mean tumor volume are presented as the mean ± SE (n=6). (B) Mean tumor weights were measured after dissection at 28 days after implantation and data are presented as the mean ± SE (n=6). (C) The tumors were excised after 4 weeks of niclosamide treatment and processed for hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining. Images of H&E-stained paraffin-embedded tumor sections were captured using a microscope. Tumor tissues were processed for IHC staining for Ki-67, cleaved caspase-3, FOXM1, and EXO1 antibody (brown staining). Scale bar, 100 µm. (D) FOXM1 and EXO1 mRNA expression was determined using qRT-PCR. β-actin mRNA was used as an internal control to normalize the data. Data are presented as the mean ± SD (n=6). *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student’s t test or one-way ANOVA test.